Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Jesduvroq Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.93

    Jesduvroq (daprodustat) Coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.93 alerts

    Get alerted when Policy 05.04.93 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for Jesduvroq to treat anemia due to chronic kidney disease in adults receiving dialysis, subject to clinical, safety, prescriber, documentation, and dosing criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyJesduvroq (daprodustat) Coverage
    Policy CodePolicy 05.04.93
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation and confirm that all initial approval criteria are satisfied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults on dialysis ≥4 monthsFDA-approved population
    12 weeksInitial authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <11 g/dLPretreatment hemoglobin
    24 mg/dayMaximum dose
    J0889Billing code

    Coverage Criteria

    Initial Therapy

    Covered for an initial authorization of 12 weeks when all of the following are met.

    Initial approval

    • Eligibility and clinical criteria: Member is 18 years of age or older; has been receiving dialysis for at least 4 months; has anemia due to chronic kidney disease; has been assessed for iron deficiency anemia and has adequate iron stores or is receiving iron supplementation before starting Jesduvroq; and has a pretreatment hemoglobin level below 11 g/dL, excluding values reflecting a recent transfusion.Age ≥18 years; dialysis ≥4 months; hemoglobin <11 g/dL
    • ESA hyporesponsiveness

      • Member requires more than 300 IU/kg per week of epoetin alfa.>300 IU/kg per week
      • Member requires at least 1.5 mcg/kg per week of darbepoetin alfa.≥1.5 mcg/kg per week
    • Safety exclusions absent: Member does not have cardiovascular abnormalities within four weeks of initiation, a history of NYHA Class IV heart failure, uncontrolled hypertension, qualifying liver disease, a history of malignancy within two years of initiation when currently receiving cancer treatment, a history of a complex kidney cyst, or a planned living kidney transplant.

      Examples of cardiovascular abnormalities include myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack. Qualifying liver disease includes ALT >2x ULN, bilirubin >1.5x ULN, current unstable liver disease, or biliary disease.

    • No concurrent ESA: Member will not use Jesduvroq with an erythropoiesis-stimulating agent (ESA).

    Continuation Therapy

    Covered for continuation authorization of 12 weeks when the following criteria are met.

    Continuation approval

    • Hemoglobin response pathway

      • Response achieved or maintained: Member has achieved or maintained a clinically meaningful increase in hemoglobin of at least 1 g/dL and the hemoglobin level is ≤11 g/dL.Increase ≥1 g/dL; hemoglobin ≤11 g/dL
      • Response not achieved or maintained

        • The dose will be increased as tolerated to a maximum of 24 mg per day.Maximum 24 mg per day
        • Member has not received 24 mg per day for more than 12 weeks without achieving a clinically meaningful increase in hemoglobin of at least 1 g/dL.

    Jesduvroq is not indicated for members who are not receiving dialysis. It is also not indicated as a substitute for transfusion when immediate correction of anemia is required.

    Initial therapy is excluded when the member has recent cardiovascular abnormalities within four weeks of initiation, including myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack; NYHA Class IV heart failure; uncontrolled hypertension; or qualifying liver disease, such as ALT >2 times the upper limit of normal, bilirubin >1.5 times the upper limit of normal, current unstable liver disease, or biliary disease.

    Initial therapy is also excluded for a malignancy within two years of initiation when the member is currently receiving cancer treatment, a history of a complex kidney cyst, or a planned living kidney transplant. Jesduvroq must not be used concurrently with an erythropoiesis-stimulating agent (ESA).

    Jesduvroq must not be used as a substitute for transfusion when immediate correction of anemia is required. It is also not indicated for treatment of anemia due to chronic kidney disease in members who are not receiving dialysis.

    Jesduvroq is considered not medically necessary when the member does not meet the applicable initial or continuation criteria, including the required clinical, laboratory, iron-status, dose-response, and concurrent-ESA requirements.

    Coding and Clinical Thresholds

    Provider Billing CodeHCPCS
    J0889daprodustat, oral, 1 mg, (for esrd on dialysis) effective 10/1/23
    Provider Services Billing CodeHCPCS
    J0889daprodustat, oral, 1 mg, (for esrd on dialysis)
    Dialysis Duration
    Minimum duration≥4 months
    Treatment settingReceiving dialysis
    Associated conditionAnemia due to chronic kidney disease
    Pretreatment Hemoglobin
    Pretreatment hemoglobin<11 g/dL
    Transfusion exclusionExclude values reflecting a recent transfusion
    Therapy phaseInitial approval

    Provider Requirements and Action Items

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required before initiating Jesduvroq. Initial authorization may be approved for 12 weeks when all applicable clinical criteria are met.

    • Member must be at least 18 years old.
    • Member must have anemia due to chronic kidney disease (CKD) and have received dialysis for at least 4 months.
    • Pretreatment hemoglobin must be <11 g/dL, excluding values reflecting a recent transfusion.
    • Member must have adequate iron stores after assessment for iron deficiency anemia or be receiving iron supplementation before starting Jesduvroq.
    Prior Authorization

    Continuation Prior Authorization Required

    Continuation prior authorization is required for each additional authorization period. Continuation authorization may be approved for 12 weeks when the hemoglobin-response, iron-status, and concurrent-therapy requirements are satisfied.

    • A clinically meaningful hemoglobin increase of ≥1 g/dL must be achieved or maintained with hemoglobin ≤11 g/dL; or, if this response has not occurred, the dose must be increased as tolerated to a maximum of 24 mg daily, the member must not have received 24 mg daily for >12 weeks without the required response, and hemoglobin must be ≤11 g/dL.

    Clinical Background

    Anemia of chronic kidney disease is associated with cardiovascular events, hospitalization, cognitive impairment, reduced quality of life, and mortality. Erythropoiesis-stimulating agents (ESAs) are the current standard treatment, but approximately 10% of dialysis-dependent patients are hyporesponsive to ESA therapy. Jesduvroq is an alternative for adults receiving dialysis who are hyporesponsive or intolerant to ESAs.

    The policy describes important safety considerations, including boxed-warning risks of thrombotic vascular events and risks of heart failure hospitalization, increased blood pressure, and gastrointestinal bleeding. ESAs also carry increased serious cardiovascular risk when administered to target hemoglobin levels >11 g/dL.

    Policy Definitions

    NYHA Class IV Heart Failure
    Physical activityUnable to carry on any physical activity without discomfort
    Symptoms at restSymptoms of heart failure are present at rest
    Effect of activityDiscomfort increases if any physical activity is undertaken
    ESA Hyporesponsiveness
    DefinitionRequires more than 300 IU/kg per week of epoetin alfa or at least 1.5 mcg/kg per week of darbepoetin alfa
    Epoetin alfa threshold>300 IU/kg per week
    Darbepoetin alfa threshold

    Initial Therapy

    Initial Therapy

    Authorization of 12 weeks may be granted when all initial approval criteria are met.

    Initial approval

    • Eligibility and clinical criteria: Member is 18 years of age or older; has been receiving dialysis for at least 4 months; has anemia due to chronic kidney disease; has been assessed for iron deficiency anemia and has adequate iron stores or is receiving iron supplementation before starting Jesduvroq; and has a pretreatment hemoglobin level below 11 g/dL, excluding values reflecting a recent transfusion.Age ≥18 years; dialysis ≥4 months; hemoglobin <11 g/dL
    • ESA hyporesponsiveness

      • Member requires more than 300 IU/kg per week of epoetin alfa.>300 IU/kg per week

    Continuation Therapy

    Continuation Therapy

    Authorization of 12 weeks may be granted when the continuation criteria are met.

    Continuation approval

    • Hemoglobin response pathway

      • Response achieved or maintained: Member has achieved or maintained a clinically meaningful increase in hemoglobin of at least 1 g/dL and the hemoglobin level is ≤11 g/dL.Increase ≥1 g/dL; hemoglobin ≤11 g/dL
      • Response not achieved or maintained

        • The dose will be increased as tolerated to a maximum of 24 mg per day.Maximum 24 mg per day

    Step Therapy Requirement

    StepPrior therapyRequirement before Jesduvroq
    1Erythropoiesis-stimulating agent (ESA) therapyMember must be hyporesponsive to ESA therapy, demonstrated by requiring >300 IU/kg per week of epoetin alfa or at least 1.5 mcg/kg per week of darbepoetin alfa.

    Quantity Limits

    Quantity Limit
    DrugJesduvroq (daprodustat)
    Maximum quantity24 mg
    Limit basisFDA-approved maximum per day
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyJesduvroq (daprodustat) Coverage
    Policy CodePolicy 05.04.93
    Change TypeNo material change
    Effective DateDec 19, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation and confirm that all initial approval criteria are satisfied.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Action ItemsClinical BackgroundPolicy DefinitionsInitial TherapyContinuation TherapyStep Therapy RequirementQuantity Limits
    No more than 12 weeks at 24 mg per day without an increase ≥1 g/dL
  1. Member's hemoglobin level is ≤11 g/dL.≤11 g/dL
  2. Iron status: Member has been assessed for iron deficiency anemia and has adequate iron stores or is receiving iron supplementation before continuing therapy with Jesduvroq.
  3. No concurrent ESA: Member will not use Jesduvroq with an erythropoiesis-stimulating agent (ESA).
  4. Epoetin Alfa Requirement
    MedicationEpoetin alfa
    Required dose>300 IU/kg per week
    Policy useDemonstrates ESA hyporesponsiveness before initiating Jesduvroq
    Darbepoetin Alfa Requirement
    MedicationDarbepoetin alfa
    Required dose≥1.5 mcg/kg per week
    Policy useDemonstrates ESA hyporesponsiveness before initiating Jesduvroq
    Continuation Hemoglobin
    Maximum continuation hemoglobin≤11 g/dL
    Applies toContinuation therapy
    Transfusion exclusionCurrent hemoglobin values reflecting a recent transfusion are excluded
    Clinically Meaningful Hemoglobin Increase
    Minimum increase≥1 g/dL
    MeasurementIncrease in hemoglobin
    Continuation useThe increase must be achieved or maintained, or dose-escalation conditions must be met
    Maximum Daily Dose
    Maximum daily dose24 mg per day
    Dose escalationIncrease as tolerated up to the maximum
    Quantity limitFDA-approved maximum of 24 mg per day
    ESA Hemoglobin Target
    Hemoglobin target>11 g/dL
    Associated therapyErythropoiesis-stimulating agents
    Safety concernTargeting levels above 11 g/dL is associated with increased serious cardiovascular risk
  5. The member must have adequate iron stores or be receiving iron supplementation before continuing therapy.
  6. Submit continuation documentation for each authorization request.
  7. Documentation Required

    Document ESA Hyporesponsiveness

    Document ESA hyporesponsiveness before initial approval. The member must meet at least one of the specified ESA dose thresholds.

    • Epoetin alfa requirement: >300 IU/kg per week.
    • Darbepoetin alfa requirement: ≥1.5 mcg/kg per week.
    • Document prior ESA treatment, including dose, frequency, duration, and response; relevant ESAs include epoetin alfa (Epogen, Procrit, Retacrit), darbepoetin alfa (Aranesp), and methoxy polyethylene glycol-epoetin beta (Mircera).
    Documentation Required

    Initial Clinical Documentation Required

    Submit the clinical records needed to initiate prior authorization review, including documentation establishing the diagnosis, dialysis history, prior ESA treatment, and response.

    • Chart notes and medical-record documentation supporting anemia due to CKD.
    • Laboratory values such as hemoglobin, ferritin, and transferrin saturation.
    • Duration the member has been receiving dialysis.
    • Prior ESA dose, frequency, duration, and treatment response.
    Documentation Required

    Continuation Laboratory Documentation

    For continuation requests, submit recent hemoglobin values and ensure the values used for review do not reflect a recent transfusion.

    • Provide recent hemoglobin documentation.
    • Exclude hemoglobin values reflecting a recent transfusion from the assessment.
    Documentation Required

    Prescriber Specialty Required

    Jesduvroq must be prescribed by or in consultation with a nephrologist or hematologist.

    • Document the prescribing specialist or the required nephrologist or hematologist consultation.
    Denial Risk

    Use Within Labeled Limitations

    Use Jesduvroq only within the policy’s labeled limitations. It is not indicated for members who are not on dialysis or as a substitute for transfusion when anemia requires immediate correction.

    • Member must be receiving dialysis for initial approval.
    • Do not use Jesduvroq as a substitute for transfusion when immediate correction of anemia is required.
    • The drug has not been shown to improve quality of life, fatigue, or patient well-being.
    Denial Risk

    Review Safety and Transplant Exclusions

    Before initial approval, confirm that none of the specified safety or transplant exclusions apply.

    • No cardiovascular abnormality, including myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack, within 4 weeks before initiation.
    • No history of NYHA Class IV heart failure, uncontrolled hypertension, or liver disease, including ALT >2× ULN, bilirubin >1.5× ULN, current unstable liver disease, or biliary disease.
    • No malignancy within 2 years of initiation when the member is currently receiving cancer treatment, and no history of a complex kidney cyst.
    • No planned living kidney transplant.
    Denial Risk

    Concurrent ESA Use Prohibited

    Jesduvroq must not be used concurrently with an erythropoiesis-stimulating agent (ESA), including epoetin alfa, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta.

    • Confirm that the member will discontinue concurrent ESA therapy before initiating Jesduvroq.
    • Reconfirm that no ESA is being used with Jesduvroq for continuation authorization.
    Denial Risk

    Criteria Not Met

    Jesduvroq is considered not medically necessary when the applicable initial or continuation criteria are not met.

    • Prior authorization may be denied when required documentation, clinical criteria, laboratory thresholds, safety requirements, specialty requirements, or nonconcurrent-ESA requirements are unmet.
    • Continuation approval may be denied when the required hemoglobin response or continuation conditions are not satisfied.
    ≥1.5 mcg/kg per week
    Member requires at least 1.5 mcg/kg per week of darbepoetin alfa.≥1.5 mcg/kg per week
  8. Safety exclusions absent: Member does not have cardiovascular abnormalities within four weeks of initiation, a history of NYHA Class IV heart failure, uncontrolled hypertension, qualifying liver disease, a history of malignancy within two years of initiation when currently receiving cancer treatment, a history of a complex kidney cyst, or a planned living kidney transplant.

    Examples of cardiovascular abnormalities include myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack. Qualifying liver disease includes ALT >2x ULN, bilirubin >1.5x ULN, current unstable liver disease, or biliary disease.

  9. No concurrent ESA: Member will not use Jesduvroq with an erythropoiesis-stimulating agent (ESA).
  10. Member has not received 24 mg per day for more than 12 weeks without achieving a clinically meaningful increase in hemoglobin of at least 1 g/dL.No more than 12 weeks at 24 mg per day without an increase ≥1 g/dL
  11. Member's hemoglobin level is ≤11 g/dL.≤11 g/dL
  12. Iron status: Member has been assessed for iron deficiency anemia and has adequate iron stores or is receiving iron supplementation before continuing therapy with Jesduvroq.
  13. No concurrent ESA: Member will not use Jesduvroq with an erythropoiesis-stimulating agent (ESA).